ProCE Banner Activity

Combination Therapy With T2D Drugs to Treat NAFLD and NASH: GLP-1 Receptor Agonists Plus SGLT2 Inhibitors

Clinical Thought

An expert shares her take on emerging strategies for combination treatment for NAFLD and NASH with GLP-1 receptor agonists plus SGLT2 inhibitors.

Released: February 02, 2023

Expiration: February 01, 2024

No longer available for credit.

Share

Faculty

Manal F. Abdelmalek

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Faculty Disclosure

Primary Author

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Manal F. Abdelmalek, MD, MPH: consultant: Bristol-Myers Squibb, NGM Biopharmaceuticals, Prometic, TaiwanJ; researcher: Allergan, Bristol-Myers Squibb, Galmed, Genfit, Gilead Sciences, Intercept, Madrigal, NGM Biopharmaceuticals, Novartis, TaiwanJ; fees for non-CME/CE services: Genfit, Intercept.